Based in the UK and Ireland, Reliance GeneMedix focuses on the development and marketing of biosimilars in European markets. The company plans to enhance its product portfolio by introducing products from its parent organization, Reliance Life Sciences. Additionally, Reliance GeneMedix has a joint venture in Malaysia, GMX Biotech, for the manufacture of recombinant human insulin. The company's current products include Temozolomide and Erythropoietin, with a focus on developing a portfolio of oncology treatments.